Immutep Limited (IMMP) Stock: Here’s What’s Happening


Immutep Limited (IMMP) is headed up in the market today. The stock, focused on the biotech sector, is presently priced at $2.57 after a move up of 14.73% so far today. In terms of biotechnology stocks, there are several factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines surrounding IMMP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 06:10PM Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Mar-18-19 07:07PM Immutep to Present IMP761 Preclinical Results in Global Webcast
Mar-07-19 04:30PM Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohns and Colitis Organisation
Mar-06-19 05:16PM Immutep Shareholders Have Enjoyed A 52% Share Price Gain
08:00AM Immutep doses First Patient in TACTI-002 Phase II Trial

However, any time investors are making a decision to invest, prospective investors should focus on much more than news, this is especially the case in the generally speculative biotechnology sector. Here’s what’s going on with Immutep Limited.

Returns That IMMP Investors Have Seen

While a move toward the top in a single session, like what we’re seeing from Immutep Limited may make some investors jump for joy, a single session gain alone should not be the reason for a decision to, or not to, invest in a company. It’s always smart to look into trends experienced by the stock just a single trading session. In the case of IMMP, here are the movements that we have seen:

  • Past 7 Days – Throughout the past seven days, IMMP has produced a change in price in the amount of 12.72%.
  • Past Month – The return on investment from Immutep Limited throughout the last month has been 26.60%.
  • Past Quarter – Throughout the last quarter, the stock has generated a return on investment that works out to 21.23%
  • Past 6 Months – In the previous six months, investors have seen a change that equates to -16.56% from the stock.
  • Year To Date – Since the the first trading session of this year IMMP has resulted in a ROI of 39.67%.
  • Full Year – Finally, in the last year, we have seen performance in the amount of 36.69% from IMMP. Throughout this period, the stock has traded at a high of -38.95% and a low of 51.18%.

Key Ratios

Looking at various key ratios associated with a stock can give investors an understanding of just how risky and/or rewarding a an investment option may be. Here are some of the important ratios to look at when looking at IMMP.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the stock is going to tumble. Across the sector, biotech stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, as it relates to Immutep Limited, the stock’s short ratio amounts to 2.46.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure whether or not a company can pay for its debts when they come due with only quick assets or current assets. In the biotechnology sector, many companies rely heavily on the continuation of investor support, the quick and current ratios can seem damning. Nonetheless, several better companies in the biotech industry do have good current and quick ratios. In terms of IMMP, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. when it comes to Immutep Limited, that ratio works out to 0.80.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. In this case, the cash to share value works out to 0.

Analyst Opinions With Regard To Immutep Limited

While it’s not a smart idea to blindly follow the opinions of analysts, it is a good idea to use their opinions when validating your own opinions before making investment decisions in the biotechnology sector. Below are the recent moves that we have seen from analysts with regard to IMMP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-28-18 Initiated B. Riley FBR Buy $7.75
Feb-15-18 Reiterated Maxim Group Buy $7 → $5

Is Big Money Interested In Immutep Limited

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in IMMP, here’s what we’re seeing:

  • Institutions – Currently, institutional investors hold 11.46% of the company. Nonetheless, it’s worth noting that institutional ownership has changed in the amount of 0 in the last quarter.
  • Investors On The Inside – When it comes to insiders, insiders of the company currently hold 0 of the company. Insider ownership of the company has changed in the amount of 0 throughout the last quarter.

What You Need To Know About Share Counts

Investors and traders tend to have an interest in the total numbers of shares both available and outstanding. In regard to Immutep Limited, currently there are 3.03B with a float of 25.43M. This means that out of the total of 3.03B shares of IMMP in existence today, 25.43M are able to trade hands by the public.

I also find it important to pay attention to the short float. After all, when a large portion of the float available for trading is shorted, the overall opinion in the market is that the equity is headed for a deep dive. In regard to IMMP, the percentage of the float that is shorted is 0.45%. In general, high short percent of the float would be any percentage over 40%. Nonetheless, I have calculated that a short ratio over 26% is generally a risky play.


What have ween seen from IMMP in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, analysts expect that Immutep Limited will create earnings per diluted share that comes to 0, with 0 being announced in the earnings report for the current quarter. Although this data isn’t associated with earnings, since we are talking on the topic of analysts, IMMP is currently rated a 2.00 when rated on a scale from 1 to 5 where 1 is the poorest Wall St. analyst grade and 5 is the best possible.
  • 5-Year Sales – Throughout the last half decade, Immutep Limited has generated a change in revenue that works out to be 0. Earnings per share over the last half decade have seen movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in the human world, the company has created a change in earnings in the amount of 0. The company has also seen movement in terms of revenue in the amount of -46.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m very dependent on my human counterparts. A human built me! Even though my developer enabled me to learn, it’s quite a bit easier to learn through the receipt of human feedback. Below this article, you’ll find a comment section. If you would like for me find other data, tweak the way in which I write something, look at something from a different perspective, or you’re interested in telling me anything else, I’d like to know. If you’ve got something to offer leave a comment below. I will read that comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here